Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine.

The Journal of Infectious Diseases Pub Date : 2022-09-28 DOI:10.1093/infdis/jiac107

Jenny S Maron, Michelle Conroy, Vivek Naranbai, Upeka Samarakoon, Tina Motazedi, Jocelyn R Farmer, Esther Freeman, Aleena Banerji, Yannic C Bartsch, David J Gregory, Mark C Poznansky, Galit Alter, Kimberly G Blumenthal

{"title":"Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine.","authors":"Jenny S Maron, Michelle Conroy, Vivek Naranbai, Upeka Samarakoon, Tina Motazedi, Jocelyn R Farmer, Esther Freeman, Aleena Banerji, Yannic C Bartsch, David J Gregory, Mark C Poznansky, Galit Alter, Kimberly G Blumenthal","doi":"10.1093/infdis/jiac107","DOIUrl":null,"url":null,"abstract":"<p><p>Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike (P = .04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγ receptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer.</p>","PeriodicalId":509652,"journal":{"name":"The Journal of Infectious Diseases","volume":" ","pages":"1231-1236"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992327/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiac107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike (P = .04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγ receptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer.

Abstract Image

查看原文本刊更多论文

对信使RNA冠状病毒病2019疫苗过敏反应后的严重急性呼吸综合征冠状病毒2抗体差异谱

2019年信使RNA (mRNA)冠状病毒病(COVID-19)疫苗接种后，高达2%的接受者出现过敏症状。与非过敏对照组(n = 18)相比，对mRNA COVID-19疫苗有立即过敏反应的个体(n = 8)在接种后的严重急性呼吸综合征冠状病毒2尖峰中对多个抗原靶点的免疫球蛋白G1 (IgG1)较低，IgG1对全长尖峰的免疫球蛋白G1明显较低(P = 0.04)。对mRNA COVID-19疫苗有立即过敏反应的个体与非过敏对照组相似地结合Fcγ受体。尽管与非过敏对照相比，有立即过敏反应的个体的调理吞噬功能总体上有降低的趋势，但过敏患者产生的功能性抗体显示出较高的调理吞噬功能与IgG1滴度之比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of Infectious Diseases

自引率

0.00%

发文量